In nursing homes, that changes a little bit. In acute care hospital settings, we recommend that contact precautions, which include gloves and gown, that health care providers ensure they're performing the appropriate hand hygiene, and that they have dedicated patient care equipment. When we do admission screening, we're able to have the facility place the patient or resident (depending on what facility type it is), if they screen positive for C auris, we recommend that those patients are placed on the appropriate transmission-based precautions. We know that asymptomatic colonization can also lead to a silent spread within a health care facility, often undetected, and so we see these larger outbreaks of C auris. If we do asymptomatic colonization, we're able to detect when a patient with C auris is not showing those signs or symptoms. Admission screening is important because we are able to identify patients or residents coming from long-term care facilities who are, as Megan indicated, asymptomatically colonized with C auris. Rankin, PhD, MPH: There are many different infection control measures that can work and beyond the basics, I want to focus on 2 primary key points that we often recommend to our health care facilities for seeing C auris, and 1 of them is admission screening. ICT: What can infection preventionists and environmental hygiene specialists do to help prevent this pathogen?ĭanielle A. It's difficult because no symptoms specifically point to C auris it's similar to infections caused by other pathogens. And if you have a wound infection from C auris, you might see redness, swelling, and drainage. If you have a bloodstream infection, you might have a fever or sepsis. However, it's often similar to infections caused by bacteria and viruses. Megan Lyman, MD: There aren't any specific signs or symptoms for C auris, which depends on the body site of where the infections are occurring. ICT: We hear about C auris in the news, but how do you recognize it? What are the symptoms? What do you see? This installment is the second in a series. Rankin, PhD, MPH, health scientist, Division of Healthcare Quality and Promotion, Prevention and Response Branch, Antimicrobial-Resistance Team, CDC. ![]() Infection Control Today® ( ICT ®), along with our colleague Chris Spivey, editorial director for Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International, reached out for answers from Megan Lyman, MD, medical officer, Mycotic Diseases Branch, CDC, and Danielle A. What specific measures should IPs and EVS take to address this issue? Preventing the spread of Candida auris ( C auris) requires the efforts of not just infection preventionists (IPs) and environmental hygiene services (EVS), but also the entire facility or community.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |